When a team presents a timeline that feels instinctively too long, trust that gut feeling. It likely signals an over-engineered solution. Complex systems never become simple; they only breed more complexity, causing timelines to expand endlessly. It's better to reset the team or the approach early on.

A prospect's unwillingness to introduce you to other decision-makers or share proprietary information (even under an NDA) is a definitive red flag. These are not signs of a slow deal, but of a dead one. It indicates a lack of serious commitment, and you should disengage to reinvest your time elsewhere.

A major source of unproductivity in drug development isn't the time spent reaching a clinical milestone. Instead, it's the 'white space' after data is received—the delay in analyzing results and making a firm go/no-go decision, which stalls the entire program.

The most effective CRO partnerships transcend a simple client-vendor dynamic. Success hinges on viewing the CRO as an integrated part of the research team, fostering close collaboration in study design and maintaining open, continuous communication.

To avoid stalled deals, continuously test the prospect's engagement. If a stakeholder consistently fails to meet small commitments—like providing requested information on time—it is a strong indicator that the deal is not a priority for them and is at high risk of stalling.

Vivtex avoids outsourcing critical R&D because external partners and CROs cannot match the speed of a startup team whose very existence depends on solving problems quickly. This internal urgency is a core competitive advantage that is lost when relying on third parties with different priorities.

Businesses often misdiagnose a lead quality problem when the real issue is a slow internal response process. A lead that waits hours or days for a callback has likely already found another provider. The lead wasn't bad; the company's speed-to-lead process failed, making the opportunity appear worthless.

The health of the CEO-CRO relationship can be measured by communication frequency. If weeks go by without a substantive conversation, the alignment is broken, indicating a dysfunctional dynamic that needs immediate correction.

For smaller biotechs, the key to a successful CRO relationship is treating them as a genuine partner. This requires moving beyond a transactional, fear-based dynamic to one of open communication and mutual respect. Biotechs should actively solicit CRO feedback, as they possess valuable cross-industry insights and can identify sponsor-side behaviors that need to change.